학술논문

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Document Type
Article
Source
In: AIDS. (AIDS, 1 February 2022, 36(2):195-203)
Subject
Language
English
ISSN
14735571
02699370